- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01675635
OxyNorm Capsules in Post-Operative Pain Study
A Double-blind, Randomized, Parallel Group Study to Compare the Efficacy and Safety, of Oxycodone Immediate-release Capsules Versus Morphine Immediate-release Tablets in Hospitalized Patients With Moderate to Severe Pain Following Surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients of either sex aged 18 to 80 years inclusive.
- Patients who have given written informed consent to participate in the study.
- Able and willing to communicate with the investigator and his/her staff.
- Free of anesthesia as assessed through question and answer interaction with nurse at which time oral medication is indicated.
- Reporting "moderate" or "severe" pain (VAS ≥ 4) related to surgery and requesting analgesics for pain relief.
Exclusion Criteria:
- Patients have developed tolerance to or dependence on narcotic analgesics and/or alcohol.
- Patients with ASA ≥ 3 .
- Have any concomitant medical condition that would be adversely affected by analgesics or confound the quantification of analgesia, or could affect the absorption, metabolism or excretion of the study drugs in any clinically significant fashion.
- Have known hypersensitivity to any of the study medications or related agents.
- Have taken analgesic medications within three hours (wash-out) prior to dosing.
- Have developed complications from the surgical procedure that would confound the study.
- Have a history of severe iatrogenic adverse experiences.
- Mothers nursing their infant during the 24 hours following study drug administration, or pregnant women.
- Patient with Nothing Per Os (NPO) as stated in patient's chart or physician's order.
- Surgery in patients with epidural anesthesia
- Patients with Severe impairment of liver at preoperative stage (ALT, AST ≥ 1.5 times upper limit) and abnormal renal function.
- Patients with medical history of recovering from abnormal surgery anesthesia.
- Patients with medical history of hypertension (Systolic blood pressure ≥ 180Hg, Diastolic blood pressure 110Hg).
- Patients with shock.
- Patients with COPD.
- According to investigator to determine, patients are in addition the inclusion criteria and exclusion criteria for any other reason than not suitable in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: OxyNorm Capsules
To determine the efficacy and safety of OxyNorm Capsules.
|
dosage:5mg,l0mg and 20mg dosage form:capsule frequency:every 6h, duration:24 hours
Other Names:
|
ACTIVE_COMPARATOR: Morphine tablet
To determine the efficacy and safety of Morphine tablet.
|
dosage: 10mg and 20mg; dosage form: tablet; frequency: every 6h; duration: 24 hours.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual Analogue Scale (VAS) in Resting Stage at 6hour (6hour±20 Minutes After Administration of First Dose)
Time Frame: Baseline and 6h (±20min)
|
To measure resting VAS at 6h(±20min) after administration of first dose, assessing the intensity of pain, and to conduct inter-group comparison Visual Analogue Scale 0 10 20 30 40 50 60 70 80 90 100 0 means no pain; 100 means pain as bad as you can image at resting stage |
Baseline and 6h (±20min)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VAS in Both Resting and Coughing Stage at 0.5h, 2h and 24h After Administration of First Dose
Time Frame: Baseline,0.5h (±5min), 2h (±10min) and 24h (±20min)
|
To measure the resting and coughing VAS as 0.5h (±5min), 2h (±10min) and 24h (±20min) after administration of first dose, assessing the intensity of pain and to conduct inter-group comparison
|
Baseline,0.5h (±5min), 2h (±10min) and 24h (±20min)
|
The Use of Rescue Analgesics During the 24-hour Observation Period
Time Frame: 24 hours after the first dose.
|
To calculate the subject who used rescue analgesics during the 4 dose interval within the 24-hour observation period and to conduct inter-group comparison
|
24 hours after the first dose.
|
VAS in Coughing Stage at 6h (6h±20min After Administration of First Dose)
Time Frame: Baseline and 6h (±20min)
|
To measure coughing VAS at 6h (±20min) after administration of first dose, assessing the intensity of pain, and to conduct inter-group comparison Visual Analogue Scale 0 10 20 30 40 50 60 70 80 90 100 0 means no pain; 100 means pain as bed as you can image applicable for both resting and coughing stage |
Baseline and 6h (±20min)
|
Sleeping Quality Assessment
Time Frame: 24 hours after administration of first dose
|
To assess Sleeping quality assessment during 24 hours after administration of first dose and to conduct inter-group comparison Sleeping quality scale
|
24 hours after administration of first dose
|
Satisfaction With Pain Control
Time Frame: 24 hours after administration of first dose
|
To assess the Satisfaction with pain control during 24 hours after administration of first dose and to conduct inter-group comparison
|
24 hours after administration of first dose
|
Comparison of the Total Amount of Study Drugs Used During the 24 Hours
Time Frame: 24 hours after administration of first dose
|
To calculate the total amount of study drugs used during the 24 hours and to conduct inter-group comparison The study drug administration is average 6 hours,so the maximal is use 4 times in 24 hours. The investigate to evaluate if the subject need to take the 2nd, 3rd and 4th dose after the mandatory the 1st dose. |
24 hours after administration of first dose
|
Collaborators and Investigators
Investigators
- Principal Investigator: XinMin Wu, Prof., Peking University 1st Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OXYC11-CN-304
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postoperative Pain
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
Ankara City Hospital BilkentRecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | SternotomyTurkey
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Aydin Adnan Menderes UniversityCompleted
-
Aydin Adnan Menderes UniversityCompletedAcute Postoperative Pain | Chronic Postoperative PainTurkey
-
Maimonides Medical CenterCompletedPOSTOPERATIVE PAINUnited States
-
University Hospital, AntwerpUnknown
-
VA Office of Research and DevelopmentRecruitingTotal Knee Arthroplasty (Postoperative Pain) | Total Hip Arthroplasty (Postoperative Pain)United States
-
VA Office of Research and DevelopmentCompletedTotal Knee Arthroplasty (Postoperative Pain) | Total Hip Arthroplasty(Postoperative Pain)United States
Clinical Trials on OxyNorm Capsules
-
Helsinki University Central HospitalUniversity of HelsinkiCompleted
-
Kures, Inc.Completed
-
Mundipharma (China) Pharmaceutical Co. LtdCompleted
-
Mundipharma (China) Pharmaceutical Co. LtdCompleted
-
Reata, a wholly owned subsidiary of BiogenAbbVie; Friedreich's Ataxia Research AllianceActive, not recruitingFriedreich AtaxiaUnited States, Australia, Austria, Italy, United Kingdom
-
Reata, a wholly owned subsidiary of BiogenAbbVieCompletedMItochondrial MyopathiesUnited States, Denmark
-
Reata, a wholly owned subsidiary of BiogenTerminatedConnective Tissue Disease-Associated Pulmonary Arterial HypertensionUnited States, Spain, Japan, Australia, United Kingdom, Canada, Germany, Belgium, Argentina, Israel, Mexico, Brazil, Czechia, Netherlands, Philippines
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting
-
AbbottQuintiles, Inc.Terminated
-
Montefiore Medical CenterCompletedIrritable Bowel SyndromeUnited States